Patents by Inventor Gary Ewart

Gary Ewart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220409587
    Abstract: Current antiretroviral therapy (ART) is a combination of 2-3 antiretroviral agents that has been successful in reducing HIV-1 RNA in the blood, and has improved the morbidity and mortality of HIV-1 infection and AIDS. Despite potent ART, eradication of HIV-1 infection remains elusive and there is potential for persistent virus replication in viral reservoirs that may continue to drive the pathogenic disease progression. Accordingly, there is a need for agents that assist in eradicating HIV-1 infection. The present invention relates to treating HIV-1 infection by administering N-carbamimidoyl-5-(1-methylpyrazol-4-yl)naphthalene-2-carboxamide in combination with antiretroviral agents.
    Type: Application
    Filed: November 25, 2020
    Publication date: December 29, 2022
    Inventors: Carolyn Luscombe, Gary Ewart, Michelle Miller
  • Patent number: 10918623
    Abstract: The present invention relates to the treatment or prevention of influenza virus infection. In particular, the present invention relates to the use of N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, in the treatment or prevention of influenza virus infection.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 16, 2021
    Assignee: Biotron Limited
    Inventors: Gary Ewart, Carolyn Luscombe
  • Publication number: 20200093796
    Abstract: The present invention relates to the treatment or prevention of influenza virus infection. In particular, the present invention relates to the use of N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, in the treatment or prevention of influenza virus infection.
    Type: Application
    Filed: February 7, 2018
    Publication date: March 26, 2020
    Applicant: Biotron Limited
    Inventors: Gary Ewart, Carolyn Luscombe
  • Publication number: 20070112013
    Abstract: The present invention relates generally to a method of retarding, reducing or otherwise inhibiting viral functional activity and, more particularly, to a method of reducing, retarding or otherwise inhibiting viral functional activity by down-regulating Vpu ion channel functional activity. Even more particularly, the present invention provides a method of treating HIV infection or AIDS by inhibiting Vpu ion channel mediated HIV replication.
    Type: Application
    Filed: December 14, 2006
    Publication date: May 17, 2007
    Applicant: Australian National University
    Inventors: Graeme Cox, Gary Ewart, Peter Gage
  • Publication number: 20070099968
    Abstract: The invention relates to compounds having antiviral activity and methods utilising the compounds to treat viral infections.
    Type: Application
    Filed: June 24, 2004
    Publication date: May 3, 2007
    Applicant: Biotron Limited
    Inventors: Peter Gage, Gary Ewart, Lauren Wilson, Wayne Best, Anita Premkumar
  • Patent number: 7179803
    Abstract: The present invention relates generally to a method of retarding, reducing or otherwise inhibiting viral functional activity and, more particularly, to a method of reducing, retarding or otherwise inhibiting viral functional activity by down-regulating Vpu ion channel functional activity. Even more particularly, the present invention provides a method of treating HIV infection or AIDS by inhibiting Vpu ion channel mediated HIV replication.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: February 20, 2007
    Assignee: Australian National University
    Inventors: Graeme Cox, Gary Ewart, Peter Gage